Rheumatoid factor revisited

Current Opinion in Rheumatology

Volumn 16, Issue 3, 2004, Pages 246-253

  Dörner, Thomas ^a   Egerer, Karl ^b   Feist, Eugen ^b   Burmester, Gerd R ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Autoimmunity; B cells; Germinal centers; Rheumatoid arthritis; Rheumatoid factor

Indexed keywords

RHEUMATOID FACTOR;

B LYMPHOCYTE ACTIVATION; CRYOGLOBULINEMIA; DEPLETION; DISEASE ASSOCIATION; GENETIC PREDISPOSITION; HEPATITIS C; HOST RESISTANCE; HUMAN; HUMORAL IMMUNITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYNOVITIS; VASCULITIS;

ANIMALS; ANTIBODY FORMATION; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; HUMANS; LYMPHOCYTE ACTIVATION; MICE; RHEUMATOID FACTOR;

EID: 1942467799     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200405000-00013     Document Type: Review

References (71)

1. Waaler E: On the occurrence of a factor in human serum activating the specific agglutination of sheep blood corpuscles. Acta Pathol Microbiol Scand 1940, 17:172-188.
2. Firestein GS: Evolving concepts of rheumatoid arthritis. Nature 2003, 423:356-361. This review highlights the most recent findings in the pathogenesis of RA and puts them into a recent perspective of our current understanding of pathways involved in the disease and therapeutic approaches, including T cell-mediated responses, T cell-independent cytokine networks, and aggressive tumorlike behavior. Interestingly, the value of autoantibodies is reemphasized by this review.
3. Franklin EC, Molman HR, Muller-Eberhard HJ, et al.: An unusual protein component of high molecular weight in the serum of certain patients with rheumatoid arthritis. J Exp Med 1957, 105:425-435.
4. Newkirk MM: Rheumatoid factors: host resistance or autoimmunity? Clin Immunol 2002, 104:1-13. This is one of the most comprehensive reviews of the pathogenetic and diagnostic role of RF in the past decade and summarizes nicely the great contributions of this group in understanding the role of RF in health and disease.
5. Lapolla A, Fedele D, Garbeglio M, et al.: Matrix-assisted laser desorption/ionization mass spectrometry, enzymatic digestion, and molecular modeling in the study of nonenzymatic glycation of IgG. J Am Soc Mass Spectrom 2000, 11:153-159.
6. Heimer R, Wolfe LD, Abruzzo JL: IgM and IgG anti-F(ab)2 antibodies in rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum 1982, 25:1298-1306.
7. Terness P, Navolan D, Moroder L, et al.: A natural IgA-anti-F(ab)2gamma autoantibody occurring in healthy individuals and kidney graft recipients recognizes an IgG1 hinge region epitope. J Immunol 1996, 157:4251-4257.
8. Pilarski LM, Piotrowska-Krezolak M, Gibney DJ, et al.: Specificity repertoire of lymphocytes from multiple myeloma patients: I. High frequency of B cells specific for idiotypic and F(ab_)2-region determinants on immunoglobulin. J Clin Immunol 1985, 5:275-284.
9. Hassan J, Feighery C, Bresnihan B, et al.: Prevalence of anti-Fab antibodies in patients with autoimmune and infectious diseases. Clin Exp Immunol 1992, 89:423-426.
10. Leadbetter EA, Rifkin IR, Marshak-Rothstein A: Toll-like receptors and activation of autoreactive B cells. Curr Dir Autoimmun 2003, 6:105-122. This review provides a very detailed review of recent experimental data of the generation of RFs and its relation to the recently discovered TLRs that may be intimately involved in RF production; therefore, innate immunity appears to play an important role in RF production.
11. Mottonen T, Hannonen P, Leirisalo-Repo M, et al.: Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999, 353:1568-1573.
12. Zvaifler NJ: The immunopathology of joint inflammation in rheumatoid arthritis. Adv Immunol 1973, 16:265-336.
13. Gause A, Berek C: Role of B cells in the pathogenesis of rheumatoid arthritis: potential implications for treatment. BioDrugs 2001, 15:73-79.
14. Krenn V, Souto-Carneiro MM, Kim HJ, et al.: Histopathology and molecular pathology of synovial B-lymphocytes in rheumatoid arthritis. Histol Histopathol 2000, 15:791-798.
15. Magalhaes R, Stiehl P, Morawietz L, et al.: Morphological and molecular pathology of the B cell response in synovitis of rheumatoid arthritis. Virchows Arch 2002, 441:415-427.
16. Weyand CM, Kurtin PJ, Goronzy JJ: Ectopic lymphoid organogenesis: a fast track for autoimmunity. Am J Pathol 2001, 159:787-793.
17. Smolen JS, Steiner G : Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003, 2:473-488. This landmark paper gives a very detailed overview of the development of therapeutics in RA that have led to an overwhelming change in the therapeutic possibilities in the past couple of years. Of outstanding importance, the agenda of the most promising agents in the years to come are listed by the article and allow an estimation of the broadness of therapeutics in the next 5 to 10 years.
18. Kim HJ, Berek C: B cells in rheumatoid arthritis. Arthritis Res 2000, 2:126-131.
19. Clausen BE, Bridges SL Jr, Lavelle JC, et al.: Clonally-related immunoglobulin VH domains and nonrandom use of DH gene segments in rheumatoid arthritis synovium. Mol Med 1998, 4:240-251.
20. Haberman AM, William J, Euler C, et al.: Rheumatoid factors in health and disease: structure, function, induction and regulation. Curr Dir Autoimmun 2003, 6:169-195.
21. Corper AL, Sohi MK, Bonagura VR, et al.: Structure of human IgM rheumatoid factor Fab bound to its autoantigen IgG Fc reveals a novel topology of antibody-antigen interaction. Nat Struct Biol 1997, 4:374-381.
22. Sutton B, Corper A, Bonagura V, Taussig M: The structure and origin of rheumatoid factors. Immunol Today 2000, 21:177-183.
23. William J, Euler C, Christensen S, et al.: Evolution of autoantibody responses via somatic hypermutation outside of germinal centers. Science 2002, 297:2066-2070.
24. Lee DM, Friend DS, Gurish MF, et al.: Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science 2002, 297:1689-1692.
25. Terato K, Harper DS, Griffiths MM, et al.: Collagen-induced arthritis in mice: synergistic effect of E. coli lipopolysaccharide bypasses epitope specificity in the induction of arthritis with monoclonal antibodies to type II collagen. Autoimmunity 1995, 22:137-147.
26. Akashi S, Saitoh S, Wakabayashi Y, et al.: Lipopolysaccharide interaction with cell surface toll-like receptor 4-MD-2: higher affinity than that with MD-2 or CD14. J Exp Med 2003, 198:1035-1042.
27. Ronaghy A, Prakken BJ, Takabayashi K, et al.: Immunostimulatory DNA sequences influence the course of adjuvant arthritis. J Immunol 2002, 168:51-56.
28. Takemura S, Braun A, Crowson C, et al.: Lymphoid neogenesis in rheumatoid synovitis. J Immunol 2001, 167:1072-1080.
29. Salomonsson S, Jonsson MV, Skarstein K, et al.: Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjögren's syndrome. Arthritis Rheum 2003, 48:3187-3201.
30. MacGregor AJ, Snieder H, Rigsy AS, et al.: Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 2000, 43:30-37.
31. Furuya T, Salstrom JL, McCall-Vining S, et al.: Wilder R L. Genetic dissection of a rat model for rheumatoid arthritis: significant gender influences on autosomal modifier loci. Hum Mol Genet 2000, 9:2241-2250.
32. Jawaheer D, Thomson W, MacGregor AJ, et al.: Homozygosity for the HLA-DR shared epitope contributes the highest risk for rheumatoid arthritis concordance in identical twins. Arthritis Rheum 1994, 37:681-686.
33. Cornelis F, Faure S, Martinez M, et al.: New susceptibility locus for rheumatoid arthritis suggested by a genome-wide linkage study. Proc Natl Acad Sci U S A 1998, 95:10746-10750.
34. Ollier WER, Silman AJ, Gosnell NG, et al.: HLA and rheumatoid arthritis: an analysis of multicase families. Dis Markers 1986, 4:85-98.
35. Silman AJ, Ollier B, Mageed RA: Rheumatoid factor detection in the unaffected first degree relatives in families with multicase rheumatoid arthritis. J Rheumatol 1991, 18:512-514.
36. Del Puente A, Knowler WC, Pettitt DJ, et al.: The incidence of rheumatoid arthritis is predicted by rheumatoid factor titer in a longitudinal population study. Arthritis Rheum 1988, 31:1239-1244.
37. Aho K, Heliovaara M, Maatela J, et al.: Rheumatoid factors antedating clinical rheumatoid arthritis. J Rheumatol 1991, 18:1282-1284.
38. Halldorsdottir HD, Jonsson T, Thorsteinsson J, et al.: A prospective study on the incidence of rheumatoid arthritis among people with persistent increase of rheumatoid factor. Ann Rheum Dis 2000, 59:149-151.
39. Ligier S, Fortin PR, Newkirk MM: A new antibody in rheumatoid arthritis (RA) targeting glycated IgG: IgM anti-IgG-AGE. Br J Rheumatol 1998, 37:1307-1314.
40. Lucey M, Newkirk MM, Neville C, et al.: Association between the IgM response to IgG damaged by glyoxidation and disease activity in rheumatoid arthritis. J Rheumatol 2000, 27:319-323.
41. Rantapää-Dahlqvist S, de Jong BAW, Berglin E, et al.: Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48:2741-2749. This case-control study in northern Sweden could show that individuals before the onset of RA had for anti-CCP 34%, IgG-RF 17%, and IgM-RF 19%. Anti-CCP antibody and IgA-RF were found to be significant predictors of RA. The presence of anti-CCP and IgA-RF predicted the development of RA, with anti-CCP antibody having the highest predictive value. Moreover, citrullination of human tissue could be identified and suggests that the production of anti-CCP can be an early autoimmunization in RA.
42. Shlomchik MJ, Euler CW, Christensen SC, et al.: Activation of rheumatoid factor (RF) B cells and somatic hypermutation outside of germinal centers in autoimmune-prone MRL/lpr mice. Ann N Y Acad Sci 2003, 987:38-50.
43. Chen T, Rimpilainen M, Luukkainen R, et al.: Bacterial components in the synovial tissue of patients with advanced rheumatoid arthritis or osteoarthritis: analysis with gas chromatography-mass spectrometry and pan-bacterial polymerase chain reaction. Arthritis Rheum 2003, 49:328-334.
44. Egerer K, Feist E, Rohr U, et al.: Increased serum soluble CD14, ICAM-1 and E-selectin correlate with disease activity and prognosis in systemic lupus erythematosus. Lupus 2000, 9:614-621.
45. Wright SD, Ramos RA, Tobias PC, et al.: CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990, 249:1431-1433.
46. Bazil V, Strominger JL: Shedding is a mechanism of downmodulation of CD14 on stimulated monocytes. J Immunol 1991, 147:1567-1574.
47. Van Snick JL, Van Roost E, Markowetz B, et al.: Enhancement by IgM rheumatoid factor of in vitro ingestion by macrophages and in vivo clearance of aggregated IgG or antigen-antibody complexes. Eur J Immunol 1978, 8:279-285.
48. Hogben DN, Devey ME: Studies on rheumatoid factor: I. The effect of rheumatoid factor on the clearance of preformed immune complexes in mice. Clin Exp Immunol 1986, 66:648-653.
49. Roosnek E, Lanzavecchia A: Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells. J Exp Med 1991, 173:487-489.
50. Jacobsson LTH, Knowler WC, Pillemer S, et al.: Rheumatoid arthritis and mortality: a longitudinal study in Pima Indians. Arthritis Rheum 1993, 36:1045-1053.
51. Newkirk MM, Lepage K, Niwa T, et al.: Advanced glycation endproducts (AGE) on IgG, a target for circulating antibodies in North American Indians with rheumatoid arthritis (RA). Cell Molec Biol 1998, 44:1129-1138.
52. Korpilahde T, Heliovaara M, Kaipiainen-Seppanen O, et al.: Regional differences in Finland in the prevalence of rheumatoid factor in the presence and absence of arthritis. Ann Rheum Dis 2003, 62:353-355.
53. Cerny EH, Farshy CE, Hunter EF, et al.: Rheumatoid factor in syphilis. J Clin Microbiol 1985, 22:89-94.
54. Watanabe K, Ohkubo Y, Funahashi Y, et al.: An investigation on rheumatoid factor of different immunoglobulin classes in hepatitis B virus carriers. Clin Rheumatol 1991, 10:31-37.
55. Jansen AL, van der Horst-Bruinsma I, van Schaardenburg D, et al.: Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol 2002, 29:2074-2076.
56. Vencovsky J, Machacek S, Sedova L, et al.: Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 2003, 62:427-430.
57. Meyer O, Labarre C, Dougados M, et al.: Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003, 62:120-126.
58. Bas S, Perneger TV, Mikhnevitch E, et al.: Association of rheumatoid factors and anti-filaggrin antibodies with severity of erosions in rheumatoid arthritis. Rheumatology (Oxford). 2000, 39:1082-1088.
59. Egerer K, Hertzer J, Feist E, et al.: sE-selectin for stratifying outcome in rheumatoid arthritis. Arthritis Rheum 2003, 49:546-548.
60. Paimela L, Gripenberg M, Kurki P, et al.: Antikeratin antibodies: diagnostic and prognostic markers for early rheumatoid arthritis. Ann Rheum Dis 1992, 51:743-746.
61. Kurki P, Aho K, Palosuo T, et al.: Immunopathology of rheumatoid arthritis: antikeratin antibodies precede the clinical disease. Arthritis Rheum 1992, 35:914-917.
62. Suzuki A, Yamada R, Chang X, et al.: Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 2003, 34:395-402. This paper completes a picture of anti-CCP ab generation by providing interesting new data on a polymorphism of peptidylarginine deiminases citrullinating enzymes (encoded by PADI genes) in rheumatoid arthritis. This case-control linkage disequilibrium study showed that PADI type 4 is a susceptibility locus for rheumatoid arthritis expressed in hematologic and rheumatoid arthritis synovial tissues.
63. Hill JA, Southwood S, Sette A, et al.: The conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB10401 MHC class II molecule. J Immunol 2003, 171:538-541. This analysis demonstrated that conversion of arginine to citrulline as a prerequisite of anti-CCP ab induction appears to be dependent on the peptide side-chain position interacting with the shared epitope. This significantly increased peptide-MHC affinity and led to the activation of CD4(+) T cells in DR4-IE tg mice.
64. Vossenaar ER, Nijenhuis S, Helsen MM, et al.: Citrullination of synovial proteins in murine models of rheumatoid arthritis. Arthritis Rheum 2003, 48:2489-2500. This study investigated the presence of anticitrulline antibodies, PAD enzymes, and citrullinated antigens in mouse models of both acute and chronic destructive arthritis. Of note, PAD4 mRNA was readily transcribed and translated by polymorphonuclear neutrophils infiltrating the synovial tissue during inflammation but not in healthy control mice. The authors concluded that citrullination of synovial antigens is apparently an active process during joint inflammation in both mice and humans, allowing the induction of anti-CCP autoantibodies in patients with RA.
65. Cambridge G, Leandro MJ, Edwards JC, et al.: Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003, 48:2146-2154.
66. Leandro MJ, Edwards JC, Cambridge G, et al.: An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002, 46:2673-2677.
67. De Vita S, Zaja F, Sacco S, et al.: Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 2002, 46:2029-2033.
68. Mariette X: Lymphomas complicating Sjogren's syndrome and hepatitis C virus infection may share a common pathogenesis: chronic stimulation of rheumatoid factor B cells. Ann Rheum Dis 2001, 60:1007-1010.
69. Baecklund E, Sundstrom C, Ekbom A, et al.: Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma. Arthritis Rheum 2003, 48:1543-1550. This is one of the largest studies analyzing the development of lymphoma secondary to RA. The authors identified an increased frequency of diffuse large B cell lymphoma in 22 of 33 NHL patients (67%) in this RA cohort. Most interestingly, 20 of 22 patients with diffuse large B cell lymphoma had high inflammatory activity, but only 6 had been treated with a disease-modifying antirheumatic drug for more than 1 year, indicating a possible association with RA disease activity.
70. Ruzickova S, Pruss A, Odendahl M, et al.: Chronic lymphocytic leukemia preceded by cold agglutinin disease: intraclonal immunoglobulin light-chain diversity in V(H)4-34 expressing single leukemic B cells. Blood 2002, 100:3419-3422.
71. Stewart JJ, Agosto H, Litwin S, et al.: A solution to the rheumatoid factor paradox: pathologic rheumatoid factors can be tolerized by competition with natural rheumatoid factors. J Immunol 1997, 159:1728-1738.